The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab - Ahlgrimm, Manfred; Pfreundschuh, Michael; Kreuz, Markus; Regitz, Evi; Preuss, Klaus-Dieter; Bittenbring, Joerg (Blood, 2011)
Keywords: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived - administration & dosage; Antineoplastic Agents - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Biological and medical sciences; Biomarkers, Tumor - analysis; Biomarkers, Tumor - genetics; Cyclophosphamide - administration & dosage; Doxorubicin - administration & dosage; Female; Gene Frequency; Hematologic and hematopoietic diseases; Humans; Immunobiology; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphoid Neoplasia; Lymphoma, Large B-Cell, Diffuse - diagnosis; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - genetics; Lymphoma, Large B-Cell, Diffuse - mortality; Male; Medical sciences; Middle Aged; Polymorphism, Single Nucleotide - physiology; Prednisone - administration & dosage; Prognosis; Randomized Controlled Trials as Topic; Receptors, IgG - genetics; Receptors, IgG - physiology; Rituximab; Survival Analysis; Treatment Outcome; Vincristine - administration & dosage; Human; Antineoplastic agent; Drug combination; Genetic variability; Hematology; Rituximab; Genotype; B cell neoplasm; Malignant hemopathy; Monoclonal antibody; FcγR receptor; Non Hodgkin lymphoma; Treatment; Lymphoproliferative syndrome; Immunotherapy; Diffuse large B cell lymphoma; Therapeutic protocol; Elderly; Cancer; Polymorphism